| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PDGRL; PRLTS |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PDGFRL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PDGFRL抗体的模拟参考文献示例(注：以下内容为假设性示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *"Monoclonal Antibody Targeting PDGFRL Suppresses Tumor Growth in Mouse Models"*
**作者**: Smith A, et al.
**摘要**: 研究开发了一种靶向PDGFRL的单克隆抗体，通过体外和小鼠模型实验证明其能有效抑制肿瘤细胞增殖和血管生成，提示其作为潜在癌症治疗手段。
2. **文献名称**: *"PDGFRL Expression in Colorectal Cancer: Prognostic Value and Antibody-Based Detection"*
**作者**: Lee J, et al.
**摘要**: 利用PDGFRL特异性抗体进行免疫组化分析，发现PDGFRL在结直肠癌组织中高表达，且与患者生存率降低显著相关，提示其作为预后生物标志物的潜力。
3. **文献名称**: *"Therapeutic Anti-PDGFRL Antibody Inhibits Angiogenesis via Blocking PDGF Signaling"*
**作者**: Zhang Y, et al.
**摘要**: 研究报道了一种阻断PDGFRL信号通路的治疗性抗体，通过体外实验证实其抑制内皮细胞迁移和血管形成，为抗血管生成疗法提供新策略。
4. **文献名称**: *"Development and Validation of a PDGFRL-Specific Antibody for Diagnostic Applications"*
**作者**: Brown K, et al.
**摘要**: 文章描述了PDGFRL抗体的开发与验证过程，证明其在ELISA和Western blot中具有高特异性，适用于疾病诊断和分子机制研究。
---
建议通过PubMed、Google Scholar等平台检索关键词“PDGFRL antibody”或“PDGFRL therapeutic/diagnostic”获取真实文献。
The platelet-derived growth factor receptor-like (PDGFRL) protein, also known as PDGFR-like protein or PDGFRL, is a member of the platelet-derived growth factor (PDGF) receptor family. Unlike classical PDGF receptors (PDGFRα and PDGFRβ), PDGFRL lacks the intracellular tyrosine kinase domain required for typical receptor signaling. It is thought to act as a decoy receptor, modulating PDGF signaling by sequestering ligands (e.g., PDGF-BB) or forming heterodimers with full-length receptors, thereby influencing cell proliferation, migration, and tissue development. PDGFRL is implicated in cancer biology, fibrosis, and vascular disorders, with studies highlighting its tumor-suppressive role in hepatocellular carcinoma, colorectal cancer, and other malignancies by inhibiting angiogenesis or metastasis.
PDGFRL antibodies are essential tools for studying its expression, localization, and interaction partners. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate PDGFRL's regulatory mechanisms in physiological and pathological contexts. Commercially available antibodies are typically raised against specific epitopes, often targeting the extracellular domain or C-terminal region. Validation includes testing for specificity in PDGFRL-knockout models or siRNA-treated cells. Researchers utilize these antibodies to explore PDGFRL's therapeutic potential, particularly in cancers and fibrotic disorders, where dysregulated PDGF signaling drives disease progression. Reliable PDGFRL antibodies are critical for advancing biomarker discovery and targeted therapy development.
×
